Education
About Us
Working with TipRanks
Follow Us
Minerva Neurosciences (NERV)
NASDAQ:NERV
NERV Stock Chart & Stats
$3.87
-$0.09(-3.83%)
At close: 4:00 PM EST
$3.87
-$0.09(-3.83%)
Day’s Range― - ―
52-Week Range$1.15 - $12.46
Previous CloseN/A
Volume1.19K
Average Volume (3M)465.60K
Market Cap
$26.57M
Enterprise Value$57.67M
Total Cash (Recent Filing)$12.29M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.30
Next Earnings
Mar 10, 2026EPS Estimate
-0.3Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.36
Shares Outstanding6,993,406
10 Day Avg. Volume1,362,901
30 Day Avg. Volume465,600
Financial Highlights & Ratios
PEG Ratio-0.11
Price to Book (P/B)>-0.01
Price to Sales (P/S)0.00
P/FCF Ratio-0.86
Enterprise Value/Market Cap2.17
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-42.37K
Enterprise Value/Ebitda-5.62
Forecast
1Y Price Target
$4.50Price Target Upside16.28% Upside
Rating ConsensusHold
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Efficacy DataPhase IIb and Phase III efficacy data suggest roluperidone is active, showing benefits for negative symptoms of schizophrenia.
Funding And Study DesignMinerva has reached alignment on the confirmatory study and secured sufficient funding for this additional study.
Regulatory ProgressManagement has aligned with the FDA to initiate a confirmatory Phase III trial, indicating progress towards potential approval.
Bears Say
Execution RisksExecution remains a risk due to the need for clarity on precise timelines for the Phase III trial.
Study DelaysFrustration exists that the company did not embark on the new study immediately after the previous trial narrowly missed its primary endpoint.
Minerva Neurosciences News
NERV FAQ
What was Minerva Neurosciences’s price range in the past 12 months?
Minerva Neurosciences lowest stock price was $1.15 and its highest was $12.46 in the past 12 months.
What is Minerva Neurosciences’s market cap?
Minerva Neurosciences’s market cap is $26.57M.
When is Minerva Neurosciences’s upcoming earnings report date?
Minerva Neurosciences’s upcoming earnings report date is Mar 10, 2026 which is in 80 days.
How were Minerva Neurosciences’s earnings last quarter?
Minerva Neurosciences released its earnings results on Nov 05, 2025. The company reported -$0.36 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.36.
Is Minerva Neurosciences overvalued?
According to Wall Street analysts Minerva Neurosciences’s price is currently Undervalued.
Does Minerva Neurosciences pay dividends?
Minerva Neurosciences does not currently pay dividends.
What is Minerva Neurosciences’s EPS estimate?
Minerva Neurosciences’s EPS estimate is -0.3.
How many shares outstanding does Minerva Neurosciences have?
Minerva Neurosciences has 6,993,406 shares outstanding.
What happened to Minerva Neurosciences’s price movement after its last earnings report?
Minerva Neurosciences reported an EPS of -$0.36 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 4.087%.
Which hedge fund is a major shareholder of Minerva Neurosciences?
Currently, no hedge funds are holding shares in NERV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Minerva Neurosciences
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone for the treatment of schizophrenia; and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. Minerva Neurosciences, Inc. has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. The company was formerly known as Cyrenaic Pharmaceuticals, Inc. and changed its name to Minerva Neurosciences, Inc. in 2013. Minerva Neurosciences, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
NERV Stock 12 Month Forecast
Average Price Target
$4.50
▲(16.28% Upside)
Technical Analysis
Bioline RX Ltd Sponsored ADR
―
Pulmatrix
―
Chemomab Therapeutics
―
Abpro Holdings
―
Aspire Biopharma Holdings
―
Ownership Overview
―
Insiders
21.08% Mutual Funds
0.89% Other Institutional Investors
74.84% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---